Clinical Trials Logo
  1. Home
  2. Chronic Pulmonary Aspergillosis
  3. NCT03656081

Chronic Pulmonary Aspergillosis and Ambisome Aerosol With Itraconazole

Chronic Pulmonary Aspergillosis Clinical Trial

Official title:
Therapeutic Efficacy Comparison of a Six-month Treatment by Itraconazole and Nebulised Ambisome® Versus Treatment by Itraconazole Alone in Non- or Mildly- Immunocompromised Patients With Chronic Pulmonary Aspergillosis: a Prospective, Randomized, Single Blind Study, (Single Aspergilloma Excluded)

Clinical Trial Summary

This study compares the therapeutic (clinical and radiological) efficacy of a six-month treatment by itraconazole and nebulised Ambisome® (liposomal amphotericin B = LAmB) versus treatment by itraconazole alone, in non - or mildly - immunocompromised patients affected by Chronic Pulmonary Aspergillosis (single aspergilloma excluded). • Control arm: Itraconazole 200 mg x 2/day associated with inactive nebulised treatment twice a week during 24 weeks. • Experimental arm: Itraconazole 200 mg x 2/day associated with nebulised LAmB, at 25 mg twice a week during 24 weeks. Follow up duration for the patients will be 24 months (12 months minimum) after discontinuation of the treatment being studied.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03656081
Study type Interventional
Source Poitiers University Hospital
Contact Céline DELETAGE
Phone +33 5 49 44 38 54
Email celine.deletage@chu-poitiers.fr
Status Recruiting
Phase Phase 3
Start date December 19, 2018
Completion date December 2029
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05064605 - Pharmacological Evaluation of Antifungal in Chronic Pulmonary Aspergillosis
Not yet recruiting NCT06244979 - iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine Phase 2
Recruiting NCT05783544 - Impact of A. Lumbricoides on Pulmonary Aspergillosis Development N/A
Completed NCT04824417 - A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis Phase 3
Recruiting NCT06447402 - A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis Phase 3
Recruiting NCT05444946 - Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome N/A
Completed NCT03920527 - Six Months Versus 12 Months of Oral Itraconazole Therapy for Management of Treatment naïve Subjects With CPA Phase 3
Not yet recruiting NCT05653193 - Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study Phase 2
Recruiting NCT03027089 - Aspergillus-specific IgG Assays for the Diagnosis of Chronic Pulmonary Aspergillosis (CPA)-Multicenter Study N/A
Active, not recruiting NCT05045391 - Pulmonary Aspergillosis in Tuberculosis Patients
Completed NCT03059992 - Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Phase 3
Available NCT05897294 - Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis